{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:10:08Z","timestamp":1761293408064,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.oooo.2016.03.020","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T02:02:57Z","timestamp":1462068177000},"page":"292-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab"],"prefix":"10.1016","volume":"122","author":[{"given":"Naseem","family":"Ghazali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Settle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua E.","family":"Lubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2016.03.020_bib1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2016.03.020_bib3","first-page":"2587","article-title":"The role of trastuzumab in the management of salivary ductal carcinomas","volume":"33","author":"Perissinotti","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oooo.2016.03.020_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oraloncology.2004.03.002","article-title":"Herceptin plus chemotherapy in relapsed and\/or metastatic salivary gland cancer","volume":"41","author":"Locati","year":"2005","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.oooo.2016.03.020_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J\u00a0Laryngol Otol"},{"key":"10.1016\/j.oooo.2016.03.020_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1758-3284-2-12","article-title":"Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine","volume":"2","author":"Sharon","year":"2010","journal-title":"Head Neck Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/2231-0770.102282","article-title":"Trastuzumab for HER2\/neu positive metastatic salivary gland carcinoma: case report and review of the literature","volume":"2","author":"Firwana","year":"2012","journal-title":"Avicenna J Med"},{"key":"10.1016\/j.oooo.2016.03.020_bib9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000355219","article-title":"Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma","volume":"6","author":"Kadowaki","year":"2013","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib11","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1002\/hed.23307","article-title":"Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature","volume":"12","author":"Krishnamurthy","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.oooo.2016.03.020_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.joms.2013.11.014","article-title":"Salivary gland carcinoma of the parotid gland: is adjuvant HER-2 targeted therapy required?","volume":"5","author":"Lee","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2016.03.020_bib13","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment","volume":"3","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.oooo.2016.03.020_bib14","first-page":"162534","article-title":"Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.oooo.2016.03.020_bib15","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics\u2013Head And Neck Tumours","first-page":"209","article-title":"Tumours of the Salivary Glands","author":"Eveson","year":"2005"},{"key":"10.1016\/j.oooo.2016.03.020_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.oraloncology.2015.03.005","article-title":"Prognostic factors in adenocarcinoma of the salivary glands","volume":"51","author":"Huang","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archoto.2011.158","article-title":"Adjuvant radiation therapy for high-grade and\/or locally advanced major salivary gland tumors","volume":"137","author":"Mahmood","year":"2011","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.oooo.2016.03.020_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.critrevonc.2014.02.002","article-title":"A\u00a0rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network)","volume":"91","author":"Cerda","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.oooo.2016.03.020_bib19","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","article-title":"Systemic therapy in the palliative management of advanced salivary gland cancers","volume":"24","author":"Laurie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib20","first-page":"368","article-title":"Update and perspectives on non-surgical treatment of salivary gland malignancies","volume":"23","author":"Airoldi","year":"2003","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.oooo.2016.03.020_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.oraloncology.2006.12.012","article-title":"Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy","volume":"43","author":"Milano","year":"2007","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib22","doi-asserted-by":"crossref","unstructured":"Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. http:\/\/dx.doi.org\/10.1002\/hed.24172. Accessed September 4, 2015. [e-pub ahead of print].","DOI":"10.1002\/hed.24172"},{"key":"10.1016\/j.oooo.2016.03.020_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2174\/1389450115666140613104403","article-title":"Detection of predictive markers for therapeutic stratification of salivary glands tumors","volume":"15","author":"Cantile","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.oooo.2016.03.020_bib24","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-14-1746","article-title":"Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: Potential therapeutic ramifications","volume":"20","author":"Mitani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2016.03.020_bib25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.28410","article-title":"Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas resistant to androgen-deprivation therapy","volume":"15","author":"Locati","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.oooo.2016.03.020_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2016.03.020_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oooo.2016.03.020_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oooo.2016.03.020_bib29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas: dependence on histological subtype","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2016.03.020_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PAT.0b013e3283484a60","article-title":"Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas","volume":"43","author":"Clauditz","year":"2011","journal-title":"Pathology"},{"key":"10.1016\/j.oooo.2016.03.020_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.2011.605","article-title":"Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer","volume":"106","author":"Ettl","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oooo.2016.03.020_bib32","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1093\/annonc\/mdt338","article-title":"Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours","volume":"24","author":"Cros","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma a clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.oooo.2016.03.020_bib35","first-page":"5675","article-title":"Amplification and overexpression of HER-2\/neu in carcinomas of the salivary gland: correlation with poor prognosis","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.oooo.2016.03.020_bib36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/jcp.50.8.661","article-title":"Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation","volume":"50","author":"Rosa","year":"1997","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.oooo.2016.03.020_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1288\/00005537-199208000-00013","article-title":"Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness","volume":"102","author":"Sugano","year":"1992","journal-title":"Laryngoscope"},{"key":"10.1016\/j.oooo.2016.03.020_bib38","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1111\/j.1365-2559.2012.04201.x","article-title":"HER-2\/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study","volume":"60","author":"Hashimoto","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.oooo.2016.03.020_bib39","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Spector","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.oooo.2016.03.020_bib40","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-09-0238","article-title":"Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance","volume":"16","author":"Williams","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2016.03.020_bib41","first-page":"353","article-title":"Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer","volume":"1846","author":"Vu","year":"2014","journal-title":"Biochim Biophys Acta"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440316300086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440316300086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T11:27:44Z","timestamp":1536751664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440316300086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2212440316300086"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2016.03.020","relation":{},"ISSN":["2212-4403"],"issn-type":[{"type":"print","value":"2212-4403"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2016.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}